Drug Safety

, Volume 32, Issue 11, pp 1089–1096

Mortality Associated with Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment

A Retrospective Cohort Study of Children, Adolescents and Young Adults Using the General Practice Research Database
  • Suzanne McCarthy
  • Noel Cranswick
  • Laura Potts
  • Eric Taylor
  • Ian C. K. Wong
Original Research Article

Abstract

Background: Following reports of sudden death in patients taking medication to treat attention-deficit hyperactivity disorder (ADHD), this study aimed to identify cases of death in patients prescribed stimulants and atomoxetine and to determine any association between these and sudden death.

Method: The UK General Practice Research Database (GPRD) was used to identify patients aged 2–21 years from 1 January 1993 to 30 June 2006 with a prescription for methylphenidate, dexamfetamine or atomoxetine. Patients were followed from the date of first prescription until whichever came first: date of death, transferred-out date, age >21 years or end of the study period.

Results: From a cohort of 18 637 patient-years, seven patients died. Cause of death was obtained for six of the patients. None were deemed to be cases of sudden death. Compared with a general population rate of sudden death in the literature, the worst-case scenario of one case of sudden death gave an incident rate ratio of 1.63 (95% CI 0.04, 9.71). Although it was not the primary outcome of the study, following reports of suicide in the cohort the standardized mortality ratio (SMR) of suicide was calculated. Due to differences in the definition of suicide used for children and adults, patients were categorized into two age groups: 11–14 years and 15–21 years. The SMR for suicide for patients aged 11–14 years was 161.91 (95% CI 19.61, 584.88). The SMR for suicide for patients aged 15–21 years was 1.84 (95% CI 0.05, 10.25).

Conclusion: This study demonstrated no increase in the risk of sudden death associated with stimulants or atomoxetine. However, an increased risk of suicide was seen. Although we cannot exclude that the medications may contribute to the increased risk of suicide, there are other factors such as depression and antisocial behaviour that frequently co-exist with ADHD, which can also predispose to teenage suicide. Clinicians should identify patients at increased risk of cardiovascular events and identify those patients at increased risk of suicide, particularly males with co-morbid conditions, and monitor them appropriately.

References

  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  2. 2.
    NICE. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults CG72. London: National Institute for Health and Clinical Excellence, 2008Google Scholar
  3. 3.
    Biederman J, Spencer T, Wilens T. Evidence-based pharmaco-therapy for attention-deficit hyperactivity disorder. Int J Neuropsychopharmacol 2004; 7: 77–97PubMedCrossRefGoogle Scholar
  4. 4.
    Atomoxetine SPC. Summary of product characteristics. Strattera® Eli Lilly and Company Limited. Electronic medicines compendium [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2007 Jul 27]
  5. 5.
    Wilens TE, Biederman J, Lerner M, and the Concerta® Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol 2004; 24: 36–41PubMedCrossRefGoogle Scholar
  6. 6.
    Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59: 829–35PubMedCrossRefGoogle Scholar
  7. 7.
    Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001; 40: 525–9PubMedCrossRefGoogle Scholar
  8. 8.
    Wilens T, McBurnett K, Pelham W, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005; 44: 1015–23PubMedCrossRefGoogle Scholar
  9. 9.
    Wilens T, Hammerness P, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2005; 66: 253–9PubMedCrossRefGoogle Scholar
  10. 10.
    Weisler R, Biederman J, Spencer T, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectrums 2005; 10: 35–43PubMedGoogle Scholar
  11. 11.
    Wernicke JF, Faries D, Girod D. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26: 729–40PubMedCrossRefGoogle Scholar
  12. 12.
    Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445–8PubMedCrossRefGoogle Scholar
  13. 13.
    Food and Drug Administration, Center for Drug Evaluation and Research. Review of AERS data for marketed safety experience during stimulant therapy: death, sudden death, cardiovascular SAEs (including stroke) [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4202B1_05_FDA-Tab05.pdf [Accessed 2006 Oct 3]
  14. 14.
    Food and Drug Administration news. FDA directs ADHD drug manufacturers to notify patients about cardiovascular adverse events and psychiatric adverse events [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01568.html [Accessed 2007 May 5]
  15. 15.
    Food and Drug Administration news: ADRQ and FDA to collaborate in largest study ever of possible heart risks with ADHD medications [online]. Available from URL: http://www.fda.gov/bbs/topics/NEWS/2007/NEW01700.html [Accessed 2007 Nov 6]
  16. 16.
    Wong IC, Murray ML. The potential of UK clinical databases in enhancing paediatric medication research. Br J Clin Pharmacol 2005; 59: 750–5PubMedCrossRefGoogle Scholar
  17. 17.
    Walley T, Mantgani A. The UK General Practice Research database. Lancet 1997; 350: 1097–9PubMedCrossRefGoogle Scholar
  18. 18.
    Smeeth L, Cook C, Fombonne E, et al. MMR vaccination and pervasive developmental disorders: a case-control study. Lancet 2004; 364: 963–9PubMedCrossRefGoogle Scholar
  19. 19.
    McCarthy S, Asherson P, Coghill D, et al. ADHD: treatment discontinuation in adolescents and young adults. Br J Psychiatry 2009; 194: 273–7PubMedCrossRefGoogle Scholar
  20. 20.
    Thompson PL, Gilbert RE, Long PF, et al. Effect of antibiotics for otitis media on mastoiditis in children: a retrospective cohort study using the UK General Practice Research Database. Pediatrics 2009; 123: 424–30PubMedCrossRefGoogle Scholar
  21. 21.
    Murray ML, de Vries CS, Wong ICK. A drug utilisation study of antidepressants in children and adolescents using the General Practice Research Database. Arch Dis Child 2004; 89: 1098–102PubMedCrossRefGoogle Scholar
  22. 22.
    Ackers R, Murray ML, Besag FMC, et al. Prioritising children’s medicines for research: a pharmacoepidemiological study on antiepileptic drugs. Br J Clin Pharmacol 2007; 63: 689–97PubMedCrossRefGoogle Scholar
  23. 23.
    Rani F, Murray M, Byrne P, et al. Epidemiology of anti-psychotic prescribing to children and adolescents in UK primary care. Pediatrics 2008; 121: 1002–9PubMedCrossRefGoogle Scholar
  24. 24.
    Clark TG, Bradburn MJ, Love SB, et al. Survival analysis, part I: basic concepts and first analyses. Br J Cancer 2003; 89: 232–8PubMedCrossRefGoogle Scholar
  25. 25.
    Wong ICK, Ackers R, Besag F, et al. Mortality following antiepileptic drug use in paediatrics (MAP). MHRA commissioned Pharmacoepidemiology Research final report. London: Medicines and Healthcare product Regulatory Agency, 2009Google Scholar
  26. 26.
    Roberts WC. Sudden cardiac death: definitions and causes. Am J Cardiol 1986; 57: 1410–3PubMedCrossRefGoogle Scholar
  27. 27.
    Wren C, O’Sullivan JJ, Wright C. Sudden death in children and adolescents. Heart 2000; 83: 410–3PubMedCrossRefGoogle Scholar
  28. 28.
    Breslow NE, Day NE. Statistical methods in cancer research. Vol. II: the design and analysis of cohort studies. Lyon: International Agency for Research on Cancer, 1987Google Scholar
  29. 29.
    Berger S, Kugler JD, Thomas JA, et al. Sudden cardiac death in children and adolescents: introduction and overview. Pediatr Clin North Am 2004; 51: 1201–9PubMedCrossRefGoogle Scholar
  30. 30.
    Medicines and Healthcare products Regulatory Agency. Yellow Card System. Drug analysis prints [online]. Available from URL: http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=742 [Accessed 2007 Sep 6]
  31. 31.
    Vetter V, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117: 2407–23PubMedCrossRefGoogle Scholar
  32. 32.
    Perrin J, Friedman R, Knilans T, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/ hyperactivity disorder. Pediatrics 2008; 112: 451–3CrossRefGoogle Scholar
  33. 33.
    James A, Lai F, Dahl C. Attention deficit hyperactivity disorder and suicide: a review of possible associations. Acta Psychiatr Scand 2004; 110: 408–15PubMedCrossRefGoogle Scholar
  34. 34.
    Cox D, Merkel L, Penberthy J, et al. Impact of methyl-phenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatr 2004; 43: 269–75CrossRefGoogle Scholar
  35. 35.
    Barkley RA, Murphy KR, DuPaul GI, et al. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc 2002; 8: 655–72PubMedCrossRefGoogle Scholar
  36. 36.
    Biederman J, Fried R, Monuteaux M, et al. A laboratory driving simulation for assessment of driving behaviour in adults with ADHD: a controlled study. Ann Gen Psychiatr 2007; 6: 4CrossRefGoogle Scholar
  37. 37.
    Wilens TE, Biederman J, Mick E, et al. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorder. J Nerv Ment Dis 1997; 185: 475–82PubMedCrossRefGoogle Scholar
  38. 38.
    Wilens T, Faraone S, Biederman J, et al. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 2003; 111: 179–85PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Suzanne McCarthy
    • 1
  • Noel Cranswick
    • 2
  • Laura Potts
    • 3
  • Eric Taylor
    • 4
  • Ian C. K. Wong
    • 1
  1. 1.Centre for Paediatric Pharmacy Research, The School of PharmacyUniversity of London and The Institute of Child Health, University College LondonTavistock SquareUK
  2. 2.Murdoch Children’s Research Institute & the Royal Children’s HospitalUniversity of MelbourneParkvilleAustralia
  3. 3.Mental Health and Neuroscience Clinical Trial UnitInstitute of PsychiatryDe Crespigny ParkUK
  4. 4.Department of Child & Adolescent PsychiatryInstitute of PsychiatryDenmark HillUK

Personalised recommendations